NASDAQ:CELZ Creative Medical Technology Q1 2025 Earnings Results & Report $0.53 -0.09 (-14.35%) Closing price 11/13/2026 03:56 PM EasternExtended Trading$0.54 +0.01 (+1.31%) As of 11/13/2026 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Creative Medical Technology missed analyst earnings expectations in its Q1 2025 results, released May 9, 2025. The company reported EPS of -$0.83 versus the -$0.52 consensus estimate, while revenue was $3 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 9, 2025TimeBefore Market Opens Creative Medical Technology EPS ResultsActual EPS-$0.83Consensus EPS -$0.52Beat/MissMissed by -$0.31One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCreative Medical Technology Revenue ResultsActual Revenue$3 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Creative Medical Technology Q1 2025 Earnings FAQ Did Creative Medical Technology beat earnings estimates for Q1 2025? Creative Medical Technology (NASDAQ:CELZ) reported earnings of -$0.83 per share for Q1 2025, missing the consensus estimate of -$0.52. The report was announced on Friday, May 9, 2025. What was Creative Medical Technology's revenue for Q1 2025? Creative Medical Technology reported revenue of $3 thousand for Q1 2025. Creative Medical Technology Earnings HeadlinesCreative Medical Technology Receives Nasdaq Bid Price Compliance NoticeNovember 13 at 4:51 PM | tipranks.comCreative Medical Technology Holdings, Inc. Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome Knee Osteoarthritis StudyOctober 22, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 15 at 1:00 AM | Base Camp Trading (Ad)Creative Medical Reports 93% Response Rate In Ultrasome Knee Osteoarthritis Pilot StudyOctober 20, 2026 | rttnews.comCreative Medical Technology Holdings Highlights Positive Ultrasome™ Pilot Data in Knee Osteoarthritis StudyOctober 20, 2026 | quiverquant.comQCreative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis StudyOctober 20, 2026 | globenewswire.comSee More Creative Medical Technology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Creative Medical Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Creative Medical Technology and other key companies, straight to your email. Email Address About Creative Medical TechnologyCreative Medical Technology (NASDAQ:CELZ) is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited. The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform. These programs remain subject to clinical development and regulatory requirements. Creative Medical Technology Holdings has historically operated from the United States and has focused primarily on research, development and potential commercialization of regenerative medicine products rather than a broad portfolio of marketed pharmaceuticals. The company’s programs and corporate activities have evolved over time, and the availability or development status of individual candidates may change as clinical and regulatory work progresses.View Creative Medical Technology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
